The BAROCCO Study (Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib): an Italian Multicenter Randomized Phase II Study of Weekly Paclitaxel vs. Cediranib-Olaparib With Continuous Schedule vs. Cediranib-Olaparib With Intermittent Schedule in Patients With Platinum Resistant High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Trial ID # NCT03314740; BAROCCO
Phase II
Drug Class DNA Damage Repair Pathway Inhibitors: PARP
Drug Name Olaparib
Alternate Drug Names AZD2281, Lynparza
Drugs in Trial Olaparib, Cediranib
Eligible Participant

Platinum resistant ovarian cancer

Patients Enrolled

123 (median Pt-free interval 1.8 months; 59% of patients had > 3 prior therapies)

Therapy Setting


Study Design

Open-Label, Randomized


PFS, evaluated per RECIST


Exploratory: BRCA status


Ola+Ced (continuous) vs Ola+Ced (intermittent) vs Pac:

PFS: 5.7 vs 3.8 vs 3.1 months, HR: 0.76 (0.49-1.17, p = 0.28); HR:1.08 (0.71-1.64, p = 0.76)

Exploratory analysis:
gBRCA WT (n=109): PFS: 5.8 vs 3.8 vs 2.1 months, HR: 0.63 (0.36-1.10, p = 0.10)

Clinically Significant Adverse Events

Ola+Ced (continuous) vs Ola+Ced (intermittent) vs Pac:
Serious AE: 2 deaths; 1 in Ola+Ced (continous), 1 in Pac
Grade 3-4 AE:


Olaparib+cediranib (continuous dosing) shows a promising trend towards improved PFS in comparison with weekly paclitaxel, in particular in BRCA WT patients


Colombo N et al. BAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib combination given with continuous or intermittent schedule in patients with recurrent platinum resistant ovarian cancer (PROC). ESMO (2019) Abstr LBA58

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.